Is Aspirin Given Lifelong in Obstetric APS?
No, aspirin is not given lifelong in purely obstetric APS—it is used during pregnancy and the postpartum period only, then discontinued if there is no history of thrombosis. 1
Duration of Aspirin Therapy in Obstetric APS
The duration of aspirin therapy depends critically on whether the patient has purely obstetric APS (pregnancy complications only) versus thrombotic APS (history of blood clots):
For Purely Obstetric APS (No Thrombotic History):
- During pregnancy: Low-dose aspirin (75-100 mg daily) combined with low molecular weight heparin (e.g., enoxaparin 40 mg subcutaneously) from positive pregnancy test until at least 34 weeks of gestation 1
- Postpartum: Continue anticoagulation for 6-12 weeks postpartum, then discontinue 2
- Between pregnancies: Low-dose aspirin may be continued in non-pregnant women with high-risk antiphospholipid antibody profiles (lupus anticoagulant positive, triple positive, or high titers), but this is for thrombosis prevention, not obstetric indication 3
For Thrombotic APS (History of Blood Clots):
- Lifelong anticoagulation is required, typically with warfarin (INR 2-3) 3
- During pregnancy, warfarin must be switched to heparin plus aspirin due to teratogenicity 2
- Warfarin is restarted 4-6 hours after vaginal delivery or 6-12 hours after cesarean delivery 2
Indications for Aspirin in Obstetric APS
Aspirin is indicated in obstetric APS to prevent recurrent pregnancy loss and obstetric complications when combined with heparin. 1
Specific Clinical Scenarios:
1. Confirmed Obstetric APS (Mandatory Treatment):
- Women with APS meeting classification criteria (persistent antiphospholipid antibodies + history of pregnancy morbidity)
- Treatment: Aspirin 75 mg + LMWH (enoxaparin 40 mg subcutaneously) from positive pregnancy test until at least 34 weeks 1
- This combination reduces miscarriage rate by 54% compared to aspirin alone 1
- Achieves live birth rates of 70% or more 4, 5
2. High-Risk Antiphospholipid Antibody Profiles: Risk factors include 6, 3:
- Lupus anticoagulant positivity
- Triple positivity (all three antibodies positive)
- Moderate to high titer antibodies
- History of previous adverse pregnancy complications
- Coexisting systemic lupus erythematosus
3. Preconception Period:
- Low-dose aspirin is recommended to start before conception in women with obstetric APS 2
- Heparin is added only after pregnancy confirmation 2
Critical Pitfalls to Avoid
Do NOT use aspirin and heparin in unexplained recurrent miscarriage without confirmed antiphospholipid antibodies—meta-analyses show no benefit and potential harm 1. This is a common error in clinical practice.
Do NOT use aspirin alone in obstetric APS during pregnancy—the combination of aspirin plus heparin is essential. Aspirin monotherapy is insufficient 1.
Do NOT continue lifelong anticoagulation in purely obstetric APS without thrombotic history—this exposes patients to unnecessary bleeding risk without evidence of benefit 3.
Evidence Quality Considerations
The 2023 BJOG guideline 1 provides the most recent high-quality recommendation, based on multiple meta-analyses showing aspirin plus heparin significantly reduces miscarriage rates (RR 0.46,95% CI 0.29-0.71). The 2019 EULAR recommendations 3 corroborate this approach with Level 1+ evidence. Both guidelines emphasize that pregnancies with APS remain high-risk even with treatment, requiring intensive fetal monitoring throughout all three trimesters 1.
The distinction between LMWH and unfractionated heparin is less critical—both are effective when combined with aspirin, though LMWH offers practical advantages (once-daily dosing, lower risk of heparin-induced thrombocytopenia and osteoporosis) 1.